ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TRT for Elderly (80 years & up)
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 191854" data-attributes="member: 3"><p><span style="font-size: 26px"><strong>Lessons From the Testosterone Trials</strong></span></p><p></p><p></p><p>Abstract</p><p>The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in <strong>788 men with a mean age of 72 years </strong>to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial,<strong> testosterone increased sexual activity, sexual desire, and erectile function</strong>. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, <strong>testosterone did not increase energy but slightly improved mood and depressive symptoms</strong>. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, <strong>testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip</strong>. In the Cardiovascular Trial, <strong>testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. </strong>Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 191854, member: 3"] [SIZE=26px][B]Lessons From the Testosterone Trials[/B][/SIZE] Abstract The Testosterone Trials (TTrials) were a coordinated set of seven placebo-controlled, double-blind trials in [B]788 men with a mean age of 72 years [/B]to determine the efficacy of increasing the testosterone levels of older men with low testosterone. Testosterone treatment increased the median testosterone level from unequivocally low at baseline to midnormal for young men after 3 months and maintained that level until month 12. In the Sexual Function Trial,[B] testosterone increased sexual activity, sexual desire, and erectile function[/B]. In the Physical Function Trial, testosterone did not increase the distance walked in 6 minutes in men whose walk speed was slow; however, in all TTrial participants, testosterone did increase the distance walked. In the Vitality Trial, [B]testosterone did not increase energy but slightly improved mood and depressive symptoms[/B]. In the Cognitive Function Trial, testosterone did not improve cognitive function. In the Anemia Trial, testosterone increased hemoglobin in both men who had anemia of a known cause and in men with unexplained anemia. In the Bone Trial, [B]testosterone increased volumetric bone mineral density and the estimated strength of the spine and hip[/B]. In the Cardiovascular Trial, [B]testosterone increased the coronary artery noncalcified plaque volume as assessed using computed tomographic angiography. [/B]Although testosterone was not associated with more cardiovascular or prostate adverse events than placebo, a trial of a much larger number of men for a much longer period would be necessary to determine whether testosterone increases cardiovascular or prostate risk. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
TRT for Elderly (80 years & up)
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top